Innovator’s Pitch Challenge

Interested in Connecting? Please contact:

Harith Hasrul
Business Development Associate
harith.hh@rudacure.com

Message the company or request a 1:1 meeting here

Company Description

RudaCure is a clinical stage bio-pharmaceutical start-up founded in 2018 and based in South Korea that is developing medicines for incurable diseases based on the most advanced life-science technologies to help improve human lives. By developing treatment techniques for intractable and incurable diseases, RudaCure will solve its unmet needs and treat the physical and mental pain for patients suffering from them. With creative pharmaceutical development and biomedical research, RudaCure is on the path to grow into a global pharmaceutical company.

Current main products in development include RCI001 for dry eye disease, which is in pre-IND phase and awaiting to start Phase 2 FDA clinical trials next year. RudaCure also plan to secure additional indications for RCI001 including conjunctivitis, keratitis and corneal ulcers. Second in development is RCI002, which is a non-opioid treatment for neuropathic and chronic pain currently in optimization stage. Other early stage products in development include treatments for atopic dermatitis, metastasis and CRPS.

Since April of 2021, RudaCure has successfully licensed-out RCI001 to Hanlim Pharm for domestic rights in a $12 million deal, and is currently looking for more investors and partners to license-out for international markets. Helping RudaCure along the way, are start-up accelerators MassChallenge and Shinhan Square Bridge, which are both helping RudaCure enter the US market.

Pitch Video

Pitch Deck

Executive Summary